Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.
- SPP allows up to $30,000 investment per eligible shareholder at $0.05 per share
- Placement raises $5 million with free attaching options exercisable at $0.0625
- Shareholder approval required at July 24 general meeting for all new shares and options
- Funds to drive diagnostics expansion in Australia and UK, plus new product development
- Post-raise share count to increase by approximately 16.5%, options by 85%
Microba Launches $6 Million Capital Raise with Dual Offer
Microba Life Sciences Limited (ASX:MAP) is embarking on a significant capital raising effort, aiming to secure up to $6 million before costs through a combination of a $5 million Placement and a $1 million Securities Purchase Plan (SPP). The SPP invites eligible shareholders to invest up to $30,000 each at the same $0.05 per share price offered to institutional investors, accompanied by one free attaching option per share exercisable at $0.0625 within three years.
The Placement, conducted in two tranches, has already seen the issue of over 91 million shares to non-related parties, with a second tranche of approximately 8.7 million shares to related and non-related parties pending shareholder approval. Alongside these shares, the company will issue an equal number of free attaching options to Placement subscribers, also subject to shareholder approval.
Use of Funds Focused on Diagnostics Growth and Product Innovation
Proceeds from the combined Placement and SPP will be directed primarily towards expanding Microba's core diagnostics business in Australia and the UK, delivering a new category-defining testing product, and bolstering working capital. The company expects to allocate over 94% of the funds to these strategic priorities, with the remainder covering transaction costs.
This capital injection comes at a pivotal moment as Microba pushes towards cashflow break-even, leveraging its proprietary bioinformatics and whole-genome metagenomic sequencing platform to maintain a competitive edge in the precision microbiome diagnostics sector.
Shareholder Approval and Dilution Considerations
All issuances of new shares and options under the SPP and the Placement Options Offer are conditional on approval at a general meeting scheduled for 24 July 2026. No securities will be issued until this approval is secured.
Assuming full subscription, the capital raise will increase the total shares on issue from approximately 609 million to 729 million, representing a dilution of around 16.5%. Options outstanding will also rise significantly, from roughly 151 million to 279 million, excluding broker options. The company has detailed potential dilution impacts for shareholders, noting that those who do not participate in the SPP may see their holdings diluted by approximately 2.74%.
Governance and Strategic Shareholder Stakes
Major shareholders include Sonic Healthcare Limited, which holds over 22% post-Placement and may increase its stake to nearly 23% under the 'creep exception' provisions of the Corporations Act. The company has structured the Placement and SPP to avoid any other investor surpassing a 20% voting power threshold, thereby managing control implications carefully.
Microba's board, led by Chair Pasquale Rombola, emphasizes the opportunity for existing shareholders to participate on equal footing with institutional investors, reinforcing alignment as the company pursues its growth ambitions.
Risks and Market Dynamics
The prospectus outlines a comprehensive range of risks, from regulatory and jurisdictional challenges inherent in healthcare diagnostics, to market acceptance, competitive pressures, and operational execution risks. Microba also faces the complexities of international expansion, data privacy compliance, and reliance on third-party partners for logistics and laboratory services.
Investors are cautioned that the securities offered are speculative and that market price volatility, liquidity constraints, and future capital needs may impact investment outcomes. The company’s financial forecasts are sensitive to foreign exchange fluctuations and pricing assumptions, particularly in the UK market.
Microba’s recent capital raise follows a period of strong core testing revenue growth and a clear path toward breakeven, supported by AI-driven efficiencies and new product development. This funding round is designed to underpin these momentum drivers and support ongoing commercialisation efforts.
Bottom Line?
Microba’s $6 million capital raise hinges on shareholder approval, setting the stage for accelerated growth but also increasing dilution and execution risks.
Questions in the middle?
- Will shareholder approval be secured without significant opposition at the July meeting?
- How will Microba manage dilution concerns among retail shareholders opting out of the SPP?
- Can the company successfully deliver its new testing product and sustain growth in competitive international markets?